| Parameter . | Age (yr) . | ||
|---|---|---|---|
| 29 . | 30–32 . | 33–35 . | |
| ANC | 3,100 | 924–1,862 (↓) | 341–1,000 (↓) |
| AMC | 412 | 60–566 | 13–1179 |
| ALC | 700 (↓) | 588–849 (↓) | 210–720 (↓) |
| CD3 | 525 (↓) | 423–645 (↓) | 259–469 (↓) |
| CD4 | 420 | 306–501 (↓) | 190–301 (↓) |
| CD8 | 98 (↓) | 112–136 (↓) | 68–154 (↓) |
| CD19 | 98 (↓) | 88–114 (↓) | 68–144 (↓) |
| NK | 49 (↓) | 47–48 (↓) | 43–90 (↓) |
| IgG | 2.8 (↓) | 6.1–15.15a | 10.9–17.6 |
| IgA | 0.19 (↓) | 0.15–0.2 (↓) | 0.16–0.3 (↓) |
| IgM | 0.85 | 0.52–0.77 | 0.66–0.76 |
| IgE | 7 | NP | NP |
| Parameter . | Age (yr) . | ||
|---|---|---|---|
| 29 . | 30–32 . | 33–35 . | |
| ANC | 3,100 | 924–1,862 (↓) | 341–1,000 (↓) |
| AMC | 412 | 60–566 | 13–1179 |
| ALC | 700 (↓) | 588–849 (↓) | 210–720 (↓) |
| CD3 | 525 (↓) | 423–645 (↓) | 259–469 (↓) |
| CD4 | 420 | 306–501 (↓) | 190–301 (↓) |
| CD8 | 98 (↓) | 112–136 (↓) | 68–154 (↓) |
| CD19 | 98 (↓) | 88–114 (↓) | 68–144 (↓) |
| NK | 49 (↓) | 47–48 (↓) | 43–90 (↓) |
| IgG | 2.8 (↓) | 6.1–15.15a | 10.9–17.6 |
| IgA | 0.19 (↓) | 0.15–0.2 (↓) | 0.16–0.3 (↓) |
| IgM | 0.85 | 0.52–0.77 | 0.66–0.76 |
| IgE | 7 | NP | NP |
Because the measurements were performed in various clinical laboratories, ↓ indicates that at least one of the measurements during this time was lower than the reference range of the corresponding laboratory. ↑ indicates that at least one measurement was higher than the controls. ANC, absolute neutrophil count; AMC, absolute monocyte count (as evaluated by automated or manual differential count); ALC, absolute lymphocyte count; NP, not performed.
After commencing intravenous immunoglobulin therapy.